First Do No Harm; How to Prevent Liver Decompensation After Radiation Therapy for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is one of the quickest growing causes of cancer death in the northern hemisphere. Transplant and resection, the only treatments considered curative, are feasible in only a small minority of patients. Consequently, the landscape of HCC treatment has greatly expanded over the past 10 years. Patients are undergoing treatment with a wide variety of nonoperative interventions, including transarterial chemoembolization and radioembolization using Yttrium-90, and an expanding array of systemic treatments, including sorafenib, regorafenib, and nivolumab.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Andrzej P. Wojcieszynski, Edgar Ben-Josef Tags: Clinical Investigation Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Liver | Liver Cancer | Liver Transplant | Physics | Radiation Therapy | Radiology | Transplant Surgery | Transplants | Urology & Nephrology